Cargando…
Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction
Although biomarkers to predict coronavirus disease 2019 (COVID-19) severity have been studied since the early pandemic, no clear guidelines on using them in clinical practice are available. Here, we examined the ability of four biomarkers to predict disease severity using conserved sera from COVID-1...
Autores principales: | Yamamoto, Kei, Ohsiro, Yusuke, Suzuki, Tetsuya, Suzuki, Michiyo, Miura, Sayaka, Nagashima, Maki, Iwamoto, Noriko, Takeuchi, Junko S., Kimura, Moto, Sugiura, Wataru, Nebuya, Satoru, Kurokawa, Masato, Ohmagari, Norio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062661/ https://www.ncbi.nlm.nih.gov/pubmed/36996138 http://dx.doi.org/10.1371/journal.pone.0279897 |
Ejemplares similares
-
Understanding IFNλ in rheumatoid arthritis
por: de Groen, Rik A, et al.
Publicado: (2014) -
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies
por: Duong, Francois H.T., et al.
Publicado: (2014) -
IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes
por: Egli, Adrian, et al.
Publicado: (2018) -
Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN‐λ3 or IFN‐λ4 show distinct phenotypes
por: De, Manjarika, et al.
Publicado: (2020) -
Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial
por: Terada-Hirashima, Junko, et al.
Publicado: (2020)